Using AI and extensive analyses of gene activity in tumours, researchers have found new, precise biomarkers to diagnose prostate cancer at an early stage through a simple urine sample.
A new, simpler and cheaper analytical method for the early detection of Alzheimer's disease could help bring blood tests into the healthcare system globally, according to a new study.
A large new study of more than 40,000 patients finds that a zero coronary artery calcium score continues to be an accurate indicator of a low risk for a coronary heart event even as a person ages.
A new PET tracer has the potential to play a critical role in the diagnosis, treatment, and monitoring of aggressive triple-negative breast cancer (TNBC), improving clinical outcomes for patients.
There is no known cure for Alzheimer’s disease (AD), although prescription drug-based treatments that can slow AD progression in some patients are starting to enter clinical use. Biomarkers, quantifiable characteristics of biological processes or pathological conditions of the body, are making it possible to help identify and measure the presence and extent of AD and its degenerative…
Blood-based biomarker (BBB) tests may represent the best weapon to combat the soaring rates of Alzheimer’s disease (AD) throughout the world. Existing clinically validated tests are currently deployed to facilitate diagnosis, to monitor disease and effectiveness of treatments, to quantify progression, and to determine if a patient is appropriate for treatment or participation in a clinical…
A new blood test, using neurofilament light chainproteins as biomarker, could lead to better diagnosis and management of amyotrophic lateral sclerosis (ALS).
New research highlights the potential of circulating tumor DNA (ctDNA) analysis as a non-invasive method to identify actionable biomarkers for breast cancer, enabling individualized therapies.
The discovery of a 'biomarker panel' could have a profound impact on the ability to identify patients at risk of developing pancreatic cancer at an earlier stage, researchers hope.
Using a new technology and computational method, researchers have uncovered a biomarker capable of accurately predicting the aggressiveness of meningioma brain tumors and breast cancers.
Certain gene alterations can serve as a prognostic and predictive biomarker for prostate cancer. Now, researchers confirm the feasibility of using NGS on this marker for precise patient stratification and treatment selection.
A sensor, similar to glucose monitoring devices, detects lung cancer biomarkers from a blood sample in just 40 minutes. The technology has potential to identify at-risk patients and tailor treatments.
Multiplex imaging can play a critical role in unravelling the tumour microenvironment. The potential and benefits of the emerging approach – a way to extract information from human tissue samples by visualising many more biomarkers than traditional microscopy – was highlighted in presentations during the 36th European Congress of Pathology in Florence, Italy. Speakers also discussed novel…
A new study confirms fibrosis as a prognostic indicator in HER2-negative, the most common breast cancer, and opens the way to antifibrotic drug treatments.
Researchers have identified biomarkers that, in conjunction with PET imaging, enable doctors to reliably distinguish between primary 4-repeat tauopathies and Alzheimer's disease.
Can a mouthwash-based test help predict head and neck cancer recurrence? A new study suggests it might.
A new method could lead to a significantly more precise and reliable diagnosis of pancreatic cancer. It is based on the selective detection of specific antibodies in blood samples.
Diagnosis and monitoring medical conditions, including cancer, diabetes, heart disease, and infections: In this opinion article, Alix Joseph (Linxens) explores the potential of sweat analysis.
Ductal Carcinoma in Situ (DCIS) often develop into more invasive forms of breast cancer. To predict which DCIS patients are likely to be affected, researchers have developed an analytic AI-based tool.
